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Hepatitis C virus (HCV) infection is a major worldwide public health concern.  It is a common cause of chronic liver 
disease and hepatocellular carcinoma.  HCV antibody and HCV RNA testing are available diagnostic studies that offer 
high degree of accuracy.  Current standard therapy includes a combination of pegylated interferon and ribavirin.   
Response rate is approximately 40% for genotype 1 and 80% for genotypes 2 and 3, respectively.  Successful treatment 
can stop the progression of chronic liver disease, reduce the need for liver transplantation, and possibly decrease the 
risk for Hepatocellular carcinoma (HCC).  Evaluating for potential treatment candidacy is an important initial step in 
the management of chronic HCV infection as not all individuals may need or qualify for the treatment.  Understanding 
the natural history, the different diagnostic modalities, the current therapeutic options and, the treatment response and 
adverse effect profiles can help the practitioners better manage chronic HCV infection. 
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1.  Introduction 
Hepatitis C virus (HCV) infection, formerly known 
as non-A, non-B hepatitis, was first identified in 1988.  The 
WHO estimates that over 170 million people globally are 
chronically infected with HCV, with 3-4 million new cases 
arising each year.  Infection with HCV is a major cause of 
chronic liver disease that is associated with cirrhosis and 
hepatocellular carcinoma (HCC).  While much effort has 
focused on the development of therapeutic agents, 
eradication of HCV infection remains a challenge.  This 
article outlines in a systematic manner the clinical 
approach in the management of chronic HCV infection 
with review of the current practice guidelines, the 
available therapeutic options, and the development of 
new therapeutic strategies. 
2.  Natural History of HCV Infection 
The natural history of HV infection was thoroughly 
reviewed by Drs. Chen and Morgan in this issue.   
Knowing the natural history of HCV infection is 
important in the management of patients with chronic 
HCV infection.  Unfortunately, the natural history of 
chronic HCV infection is incompletely defined owing to 
the lack of long term prospective studies.  Retrospective 
studies have provided a wide range estimate of the 
proportion (17 to 55%) of chronic infection leading to 
cirrhosis within 20 years.  The proportion estimated by the 
available prospective studies is much less.  The NIH 
Consensus Statement in 2002 estimates the rate of 
development of cirrhosis in the order of 10 to 15%. 
Current natural history data suggest that progression 
of HCV infection is slow; the time course for the 
development of cirrhosis is estimated to be in the order of 
20 to 30 years.  Although the mortality related to liver 
disease in the infected population is described as higher 
(4.1 versus 1.3 percent) [1] than age-matched control 
population, the overall mortality has shown to be similar 
[2].  This may suggest that not all patients infected with 
HCV develop chronic infection or have the same degree of 
liver disease progression. 
Several factors have been identified to influence the 
rate of progression to cirrhosis in the HCV chronically 
infected population.  Unfavourable factors include male 
age, age >40 years at infection, significant alcohol 
consumption >30 g/day, and co-infection with human 
immunodeficiency virus (HIV) or hepatitis B virus (HBV) 
[3-6].  Recent data also identified diabetes and obesity as 
unfavourable risk factors [7].  On the other hand, female 
sex and younger age at infection are regarded to be 
associated with a lower rate of progression to cirrhosis [8].  
No association has been shown between the progression 
of liver disease and HCV RNA and ALT levels. 
Those with chronic HCV infection that progress to 
cirrhosis, most but not all, develop subsequent 
complications that eventually lead to hepatic 
decompensation.  The most common indication of 
decompensation is usually ascites.  Other complications 
that follow include variceal bleeding, encephalopathy and 
jaundice [9].  With the onset of cirrhosis, HCC occurs at a 
rate of 1-4% per year [10].   
3.  Clinical Presentation of HCV Infection 
HCV infection may result in an acute episode of 
hepatitis which usually runs a mild clinical course with 
minimal risk of developing fulminant hepatic failure.   
However, the risk of developing a chronic infection after 
an acute episode of hepatitis C is high.  Positive HCV 
RNA has been shown in 80 to 100 percent of those 
infected, and up to 80 percent with persistently elevated 
serum aminotransferase values [11,12]. 
Most patients with chronic HCV infection experience 
no symptoms.  The remaining has mild and non-specific 
symptoms such as fatigue, arthralgia, myalgia, anorexia 
weight loss and depression.  It is unclear whether these 
symptoms can be solely attributed to HCV infection or 
whether they are caused by a concomitant medical or 
psychiatric condition.  However, these symptoms are Int. J. Med. Sci. 2006, 3  64
reported to affect the quality of life which in turn can be 
improved after treatment [13,14]. 
Symptoms in HCV infection do not appear to be 
linked to disease activity; neither do appear to be 
correlated with serum aminotransferase levels or liver 
histological findings [15,16].  In addition, serum 
aminotransferase level has not been shown to predict liver 
histological status [17,18].  The proportion of serum 
aminotransferase level elevation varies among patients 
with chronic HCV infection.  Approximately one third of 
those chronically infected never develop elevated 
aminotransferase levels, while the remaining has a wide 
range of levels.  Histological evidence of chronic 
inflammation is present in all patients but typically to a 
l e s s e r  d e g r e e  i n  t h e  g r o u p  w i t h  n o r m a l  s e r u m  
aminotransferase levels [16]. 
Once cirrhosis develops, symptoms may be more 
evident and hepatic decompensation develops at a rate of 
approximately 4 percent per year but not in all patients 
[9].  The first sign of decompensation is usually ascites, 
subsequently followed by upper gastrointestinal bleeding, 
encephalopathy and jaundice.  Hepatic decompensation 
leads to increased mortality in the chronic HCV infected 
population while HCC, which rarely occurs in the non-
cirrhotic, accounts for the increased mortality as well. 
4.  Diagnosis of HCV Infection 
Screening 
Routine screening should be directed to a population 
with a higher prevalence of HCV infection than the 
general population [19].  There are several high-risk 
groups for HCV infection.  Individuals with a history of 
transfusion of clotting factors prior to 1987, as well as 
blood products or received organ transplantation prior to 
1992 should be tested.  Patients with a recent or remote 
history of injection drug use, on chronic hemodialysis, 
infants born to mothers with HCV or those with evidence 
of unexplained liver disease should all be screened as 
well.  In addition, all patients with HIV infection should 
be screened since approximately 5-10% of those with 
positive HCV infection are co-infected with HIV [20]. 
Testing Strategies  
1) Serologic Testing 
The first-line diagnostic approach in the clinical 
setting is the utilization of the enzyme-linked 
immunoassay (ELISA) test, which tests for antibodies to 
HCV.  The current third generation of ELISA provides a 
sensitivity and specificity of 99% in as early as 7 to 8 
weeks post infection [21]. 
2) Molecular Testing 
Those who are positive for anti-HCV can then have 
HCV RNA levels tested to document viremia.  Detection 
of HCV RNA levels can be accomplished by reverse 
transcription polymerase chain reaction (PCR) tests, 
which are highly sensitive.  These tests are not only useful 
in the confirmation of HCV infection, but also in the 
evaluation of response to antiviral therapy when patients 
are undergoing treatment.  In addition, there are instances 
when immuno-competency is in question, a negative anti-
HCV can be further evaluated by a HCV RNA test.  HCV 
RNA can be measured either quantitatively or 
qualitatively, which can approach a low limit of detection 
of 50 IU/ml or 100 viral copies/ml as early as 1-2 weeks 
post infection [21].  Therefore, when acute infection is 
suspected, HCV RNA can be tested before the appearance 
of HCV antibodies. 
3) Genotype Testing 
Once HCV infection is confirmed, the genotype of 
the HCV virus could be determined.  The genotype of the 
HCV virus could play an important role when planning 
for treatment since it can predict the response rate to 
treatment and can guide the length of treatment [22-26].  
There are six major genotypes of HCV currently 
recognized, numbered 1-6, and many subtypes.  The 
prevalence of a particular genotype varies geographically.  
In the United States and Europe, over 90% of the HCV 
infections are of genotypes 1, 2 and 3, with genotype 1 
being the most common.  Genotype 4 is common in Africa 
and the Middle East, while genotypes 5 and 6 are the least 
prevalent and are found primarily in South Africa and 
Southeast Asia respectively. 
4) Role of Liver Biopsy 
A liver biopsy is not required for the diagnosis of 
HCV infection.  Although several histopathological 
features of HCV infection have been described, these are 
non-specific and cannot be relied on in making a 
diagnosis [27].  However, a liver biopsy is routinely done 
prior to the treatment of HCV infection, although the 
utility of it is still debated.  Regardless, a liver biopsy can 
provide several benefits.  The histological findings can 
determine the staging of the liver disease and hence can 
provide the prognosis.  If cirrhosis is found in a liver 
biopsy, patients can be screened periodically for 
hepatocellular carcinoma, since most will happen after the 
onset of cirrhosis.  Periodic screening of esophageal 
varices is also warranted with the findings of cirrhosis.  In 
addition, the liver biopsy can help in the selection of 
patients for treatment.  Those patients found to have mild 
chronic hepatitis on liver biopsy can often opt to be 
monitored rather than treated, particularly if they have 
other comorbidities.  Furthermore, a pre-treatment liver 
biopsy can help guide the treatment process particularly 
when patients are experiencing adverse effects. For 
example, in patients with advanced stage of liver disease, 
the treatment should be planned timely and the threshold 
to discontinue treatment should be higher since effective 
treatment will slow down disease progression.  Liver 
biopsy may also help in diagnosing other co-existing liver 
diseases, like hepatic steatosis, a common presentation in 
HCV infected patients. 
5.  Approach to Treatment of Chronic HCV Infection 
Initial Evaluation of Patients with Chronic HCV 
Infection 
1) History 
Obtaining a thorough clinical history is important as 
the initial step in consideration for treatment.  The history 
can provide clues regarding the timing of HCV infection 
and hence the possible duration of chronic liver disease 
which can give a more accurate prognosis.  Elements in 
the history that help identify the possible timing of the 
infection or the duration of the liver disease include:  prior 
history of injection drug use, former history of transfusion 
of blood products, unexplained history of abnormal liver 
transaminases, or a known history of contact exposure to 
HCV.  The clinical history can also disclose other 
concurrent medical conditions that may pose as barriers 
for treatment such as major depressive disorders, Int. J. Med. Sci. 2006, 3  65
underlying autoimmune diseases, thyroid disorders, 
pregnancy, etc.  In addition, the history can identify other 
factors such as alcohol use or abuse which may suggest 
possible accelerated disease progression or hints 
decreased responsiveness to treatment. 
2) Physical Examination 
The physical exam can further add information 
regarding the severity of the liver disease; unfortunately, 
physical signs may not be evident until patients develop 
cirrhosis.  The presence of ascites and encephalopathy are 
diagnostic of decompensated liver disease.  Other physical 
signs that may suggest cirrhosis and portal hypertension 
include the presence of splenomegaly, firm liver edge and 
spider angioma. 
3) Laboratory Tests 
Laboratory studies can provide useful values to 
predict the progression of liver disease.  Laboratory 
studies should include a complete blood count (CBC), 
prothrombin time (PT), international normalized ratio 
( I N R ) ,  a n d  a  l i v e r  p a n e l .   A l t h o u g h  t h e  s e r u m  
aminotransferase level correlates poorly with liver 
histology, the ratio of aspartate aminotransferase (AST) to 
alanine aminotransferase (ALT) >1 is a dependable 
marker for cirrhosis [28,29].  Increased INR and 
thrombocytopenia is also seen more frequently in cirrhosis 
[30].  Additional laboratory studies that are useful include 
α-fetoprotein (AFP) level, HCV genotype and RNA level.  
The AFP is widely used in screening of HCC, while HCV 
genotype and RNA level can later guide the treatment 
process. 
4) Radiographic Studies 
Several modalities of radiographic tests are used to 
evaluate patients with chronic HCV.  Ultrasound is useful 
in the evaluation for evidence of portal hypertension such 
as splenomegaly, recanalization of the umbilical vein, 
ascites, etc.  It is also useful in the screening of HCC 
although CT scan or MRI provides higher sensitivity for 
this purpose [31].  Liver-Spleen scans can provide 
additional information when cirrhosis is suspected.   
Colloid shifting and evidence of splenomegaly is 
suggestive of cirrhosis. 
Selection of Patients for Treatment of Chronic HCV 
1) Why to Treat HCV Infection 
The treatment of HCV is justified by the natural 
history and the outcome of chronic infection and liver 
injury that is associated with cirrhosis, hepatic 
decompensation, development of HCC, and mortality.  In 
addition, HCV infection has been linked to a variety of 
extra-hepatic manifestations such as autoimmune 
diseases, lymphoma, monoclonal gammopathies and 
cryoglobulinemia.  Some of these extra-hepatic 
complications could lead to severe systemic disease and 
damage to other organs before significant liver disease is 
evident.  These extra-hepatic manifestations could also 
impair significantly the quality of life.  The goal of 
treatment is to stop or slow down disease progression and 
prevent complications due to chronic HCV infection by 
sustained suppression of HCV replication. 
2) Who Should Receive Treatment 
As a general rule, treatment should be considered for 
all patients with virologic or histologic evidence of chronic 
infection.  Therefore, every patient with chronic HCV is a 
potential candidate for treatment.  The decision to treat is 
never clear-cut, but rather it is weighed by the severity of 
disease, the predicted success rate, the anticipated adverse 
effects and the cost and availability of the drugs.  The 
decision to treat should never be made by the physician 
alone; it should be made only after educating patients 
regarding the disease, the prognosis, the treatment 
options, the outcomes and the alternatives if chose not to 
be treated (Fig 1).  Taking all these factors in 
consideration, there are several guidelines currently 
available to help decide which population of patients 
should undergo therapy.  The American Association for 
the Study of Liver Diseases (AASLD) recognizes three 
categories of patients: those in whom therapy is widely 
accepted, those in whom therapy should be 
individualized and, those in whom therapy is 
contraindicated [32]. 
Based on these guidelines, therapy is widely 
accepted for those who are at least 18 years old, who have 
evidence of abnormal ALT values, whose liver biopsy 
shows chronic hepatitis with significant fibrosis (Metavir 
score ≥ 2, Ishak score ≥ 3), who have compensated liver 
disease (total serum bilirubin < 1.5 g/dL, INR < 1.5, 
albumin > 3.4 g/dL, platelet count >75, 000 k/mm3, and 
no evidence of hepatic encephalopathy or ascites).  In 
addition, patients should have acceptable hematological 
and biochemical indices (hemoglobin > 13 g/dL for men 
and > 12 g/dL for women, neutrophil count > 1.5 k/mm3, 
creatinine < 1.5 mg/dL).  If there is a pre-existing history 
of depression, it should be well controlled.  When patients 
have been treated previously for HCV infection, they 
should be considered as long as all the above criteria are 
met.  However, the most important factor for 
consideration of treatment is the patient’s willingness to 
be treated and to conform to the treatment requirements. 
Treatment is generally contraindicated in patients 
with major uncontrolled depressive disorders, untreated 
hyperthyroidism or any other severe concurrent disease, 
such as poorly controlled hypertension or diabetes, 
obstructive pulmonary disease, or significant heart 
disease.  Patients with autoimmune hepatitis or other 
conditions known to be exacerbated by interferon and 
ribavirin or known to have hypersensitivity to these drugs 
should not receive treatment.  Treatment is also 
contraindicated in those who are post renal, heart, or lung 
transplant recipients.  In addition, children under 3 years 
of age, pregnant patients or those unwilling to comply 
with adequate contraception should not be treated either. 
Treatment should be individualized in patients with 
the following characteristics:  1) acute HCV infection; 2) 
coinfection with HIV; 3) under 18 years of age; 4) chronic 
renal disease, on or not on hemodialysis; 4) 
decompensated cirrhosis; 5) liver transplant recipients; 6) 
persistently normal ALT values; 7) failed prior treatment 
and; 8) current users of illicit drugs or alcohol but willing 
to participate in substance abuse programs.  Some of these 
were further discussed by Dr. Hoefs et al in the separated 
article in this issue. 
3) Available Antiviral Therapy 
The current standard of therapy includes the 
combination of weekly pegylated interferon and daily 
ribavirin.  The treatment duration and dosage, as well as 
the response rate depend on HCV genotype, HCV load 
and other factors.  The pegylated interferon is an 
interferon that has a polyethylene glycol moiety attached, Int. J. Med. Sci. 2006, 3  66
this results in a longer half-life and improved 
pharmacokinetics which allows once-weekly 
subcutaneous injections as compared to the non-pegylated 
interferons, which required three times weekly injections.   
There are currently two available pegylated 
interferons, α2a and α2b.  Two large randomized studies 
compared interferon plus ribavirin with pegylated 
interferon plus ribavirin [24,25].  One study tested α2a 
(fixed dose of 180 μg) with ribavirin dose adjusted based 
on weight (1000 mg for weight <75 kg, 1200 mg for weight 
>75 kg); while the other tested α2b (adjusted by weight at 
1.5 μg/kg) with a fixed dose of ribavirin of 800 mg.  Both 
studies reported similar efficacies as well as adverse effect 
profiles.  The sustained virological response (SVR) rates 
with the combination of pegylated interferons and 
ribavirin are reported to be much superior as compared 
with the combination of interferon and ribavirin.  The SVR 
were approximately 40% for genotype 1 and 80% for 
genotypes 2 and 3, respectively [24,25].  However, there 
are no reported studies with direct comparisons between 
these two pegylated interferons.  The variables reported to 
be associated with SVR include a genotype other than 1, 
viral load <2 million copies/ml, age <40, and lower body 
weight.  In addition, these studies provided evidence that 
early virological response (EVR) defined as HCV viral 
load is decreased by at least 2 log or to an undetectable 
level at 12 weeks of treatment predicts a high possibility 
of SVR. 
In a separate study, pegylated interferon α2a was 
u s e d  w i t h  r i b a v i r i n  e i t h e r  a d j u s t e d  b y  w e i g h t  o r  f i x e d  
dose of 800 mg, for 24 vs. 48 weeks [26].  From this study, 
it appears that SVR rate for genotype 1 was significantly 
superior when α2a peg-interferon was given with weight-
adjusted dose of ribavirin for 48 weeks vs. when given for 
24 weeks or when given with low dose of 800 mg of 
ribavirin.  However, for genotypes 2 and 3, SVR rate was 
similar regardless of the dose of ribavirin or the duration 
of the treatment.  Besides genotypes 1, 2 and 3, other 
genotypes were not representative in the above 
mentioned studies, but in general, genotypes 4, 5 and 6 
are thought to respond more like genotype 1.  Thus, 48-
weeks treatment is recommended for these genotypes. 
The current guidelines support the use of a 
pegylated interferon α plus ribavirin as the first line 
therapy.  For genotype 1, ribavirin should be dosed based 
on weight (i.e., 1000 mg/day for weight <75 kg, 1200 mg 
for weight >75 kg/day), and the duration of treatment 
should be anticipated for 48 weeks.  On the other hand, 
genotypes 2 and 3 will require only ribavirin 800 mg/day, 
and the duration of treatment is recommended for 24 
weeks [32]. 
4) Follow-up of Treatment 
Once treatment has been decided for a particular 
patient, routine follow-up is planned.  Pre-treatment 
baseline laboratory values should be obtained including 
CBC, complete metabolic panel, PT and HCV viral load.  
Patients should return 2 weeks after initiation of therapy 
and subsequently every 4 weeks.  At these encounters, the 
above routine laboratory studies should be obtained as 
well to monitor for signs of adverse effects due to the 
drugs.  Repeat HVC viral load should be repeated at week 
12 of treatment to document EVR.  The decision to 
continue treatment after week 12 would then be 
determined based on individual response to treatment 
(EVR), tolerance to the drugs, laboratory profiles, and the 
pre-treatment assessment of the severity of the liver 
disease.  During each follow-up, signs and symptoms of 
possible adverse effects should be evaluated.  If treatment 
is continued in the presence of adverse effects, dose 
adjustments can be considered.  On the other hand, a 
particular adverse effect can be treated or monitored 
without lowering medication dosages depending on its 
severity.  Once the course of treatment is completed, a 
qualitative HCV viral load must be obtained to document 
end of treatment response (ETR).  The same test should be 
done 6 months later to evaluate for SVR. 
5) General Measures 
Several general measures should be addressed for 
every patient with chronic HCV infection regardless of 
treatment candidacy.  Alcohol abstinence should be 
recommended to all patients as this may accelerate the 
progression of liver disease.  Hepatotoxic drugs should 
also be avoided, as patients with advanced fibrosis have 
little reserve for additional injury.  Immunization against 
hepatitis A and B should be given if patients do not 
exhibit markers of prior exposure.  Although there is no 
data to support a particular diet for patients with HCV 
infection, those who have late stage liver disease may be 
counselled regarding low sodium diet to avoid fluid 
retention.  In general, a healthy diet is recommended 
particularly for those with high body mass index since 
there is data suggesting that obesity accelerating fibrosis. 
6.  Research Direction 
Although significant advances in therapeutic options 
have improved the outcome in the management of HCV 
infection, many challenges remain ahead.  The proportion 
of chronic HCV not responding to the available drugs is 
far from insignificant, particularly for genotypes other 
than 2 and 3.  Furthermore, these drugs are not devoid of 
adverse effects, some of which are severe enough to 
warrant discontinuation of the treatment.  In addition, the 
large proportion of patients with comorbidities and those 
who fall into the category of “special groups”, represent 
even greater challenge.  On the other hand, it is 
encouraging that new therapeutic options continue to 
emerge.  Viramidine is a prodrug of ribavirin that does 
not accumulate in erythrocytes and is preferentially 
converted to ribavirin in liver.  A phase II study indicated 
a lower rate of anemia induced by viramidine than 
ribavirin.  However, its efficacy remains to be determined 
by ongoing clinical trials.  Several types of HCV-specific 
protease inhibitors have been developed.  Although the 
early results appear very promising, their safety and 
efficacy remain to be confirmed by phase III trials.  In 
addition, active research is being focused on searching 
new anti-HCV agents.  The ideal therapy in the future will 
likely focus on drugs with high response rate for both 
treatment naïve and treatment refractory patients, while 
providing an improved adverse effect profile and a 
shorter duration of treatment. 
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Figure 1.  Algorithm for the management of chronic HCV infection 
 